Immune cells in a heterotopic lamb-to-pig bronchial xenograft model.
We developed our porcine model to elucidate the cellular rejection mechanisms of xenografts. Bronchial segments from a donor lamb were implanted into domestic pigs. The immunosuppressive regimens consisted of no immusuppression, or of daily oral cyclosporine A (CsA) 15 mg/kg, or of everolimus, 1.5 mg/kg, or of both. Implants were serially harvested during 17 days. Epithelial damage and obliteration were graded histologically, followed by a count of CD4+, CD8+, MHC class II-expressing cells, and macrophages. Furthermore, we studied the pharmocokinetics of everolismus. Epithelial damage preceded luminal obliteration, which was eventually total, except when both drugs had been given. In xenografts, an influx of cells with CD8+ cells dominating peaked on day 9, thereafter declining, except in the combination drug group. There, the immunological reaction was delayed and blunted, with CD4+ cells dominating. More macrophages appeared in xenografts than in allografts except with the combination CsA and everolimus. A dose of 1.5 mg/kg everolimus yields adequate blood concentrations for porcine studies. In this xenograft model, chronic rejection appears to be caused by an immune response to the graft, but it is more short-lived than the response in allografts. The combination of CsA and everolimus was able to blunt the response and delay the subsequent obliteration.
Maasilta
Paula K
PK
Department of Surgery, Helsinki University Hospital, HUS, Finland. paula.maasilta@helsinki.fi
Vainikka
Tiina L S
TL
Alho
Hanni S
HS
Salminen
Ulla-Stina
US
D000818:Animals; D001980:Bronchi / Q000473:pathology / Q000637:transplantation*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016572:Cyclosporine / Q000627:therapeutic use; D000068338:Everolimus; D006084:Graft Rejection; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D007150:Immunohistochemistry; D012756:Sheep; D020123:Sirolimus / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous
D000949:Histocompatibility Antigens Class II; D016572:Cyclosporine; D000068338:Everolimus; D020123:Sirolimus